GV-58 is a novel N- and P/Q-type calcium (Ca) channel agonist with EC 50 s of 7.21 and 8.81 μM, respectively. GV-58 slows the deactivation of channels, resulting in a large increase in presynaptic Ca entry during activity. GV-58 can be used in lambert-eaton myasthenic syndrome (LEMS) research.
GV-58 (50 μM; 30 min) restores function in LEMS passive transfer neuromuscular junction. has not independently confirmed the accuracy of these methods. They are for reference only.Cell Viability AssayCell Line:
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Tarr TB, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013 Jun 19;33(25):10559-67.[2]. Tarr TB, et al. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. J Physiol. 2014 Aug 15;592(16):3687-96.
溶解度数据
In Vitro: DMSO : 75 mg/mL (200.27 mM; Need ultrasonic)配制储备液